Macular Degeneration Treatment Market - 2022
The Macular Degeneration Treatment Market was valued at USD 9.3 billion in 2022 and is anticipated to reach by , at a CAGR of 0.066 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Macular Degeneration Treatment Market.
This report delivers a comprehensive overview of the Macular Degeneration Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Macular Degeneration Treatment Market. The Macular Degeneration Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
Macular Degeneration Treatment Market Scope:
By Type
This report delivers a comprehensive overview of the Macular Degeneration Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Macular Degeneration Treatment Market. The Macular Degeneration Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Macular Degeneration Treatment Market.
This report delivers a comprehensive overview of the Macular Degeneration Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Macular Degeneration Treatment Market. The Macular Degeneration Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
Macular Degeneration Treatment Market Scope:
By Type
- Wet Macular Degeneration
- Dry Macular Degeneration
- Drugs
- Surgery
- Others
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Others
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Genentech USA, Inc.
- REGENXBIO Inc.
- Bausch Health Companies Inc.
- F Hoffmann-La Roche Ltd.
- Santen Pharmaceutical Co., Ltd.
- GNH Pharmaceuticals USA LLC
- Iveric Bio Inc.
- Allergan Inc.
This report delivers a comprehensive overview of the Macular Degeneration Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Macular Degeneration Treatment Market. The Macular Degeneration Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Therapeutic Innovations
4.1.1.2. Rising Clinical Trials for Macular Degeneration Drugs
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Drugs
4.1.3. Opportunity
4.1.3.1. Technological Advancements in Treatment Options
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Wet Macular Degeneration *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dry Macular Degeneration
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Drugs *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Anti-vascular Endothelial Growth Factor
8.2.4. Others
8.3. Surgery
8.4. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ophthalmic Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Novartis AG *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Regeneron Pharmaceuticals Inc.
12.3. Genentech USA, Inc.
12.4. REGENXBIO Inc.
12.5. Bausch Health Companies Inc.
12.6. F Hoffmann-La Roche Ltd.
12.7. Santen Pharmaceutical Co., Ltd.
12.8. GNH Pharmaceuticals USA LLC
12.9. Iveric Bio Inc.
12.10. Allergan Inc. (*LIST NOT EXHAUSTIVE)
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Therapeutic Innovations
4.1.1.2. Rising Clinical Trials for Macular Degeneration Drugs
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Drugs
4.1.3. Opportunity
4.1.3.1. Technological Advancements in Treatment Options
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Wet Macular Degeneration *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dry Macular Degeneration
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Drugs *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Anti-vascular Endothelial Growth Factor
8.2.4. Others
8.3. Surgery
8.4. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ophthalmic Clinics
9.4. Ambulatory Surgical Centers
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. COMPETITIVE LANDSCAPE
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. COMPANY PROFILES
12.1. Novartis AG *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Regeneron Pharmaceuticals Inc.
12.3. Genentech USA, Inc.
12.4. REGENXBIO Inc.
12.5. Bausch Health Companies Inc.
12.6. F Hoffmann-La Roche Ltd.
12.7. Santen Pharmaceutical Co., Ltd.
12.8. GNH Pharmaceuticals USA LLC
12.9. Iveric Bio Inc.
12.10. Allergan Inc. (*LIST NOT EXHAUSTIVE)
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
